Abbott And Medtronic Collaborate To Enhance Diabetes Treatment

Abbott has unveiled an innovative global partnership with Medtronic aimed at developing an integrated continuous glucose monitoring (CGM) system. This system will leverage Abbott's cutting-edge FreeStyle Libre technology and connect seamlessly with Medtronic's automated insulin delivery (AID) and smart insulin pen solutions.

By combining Abbott's CGM sensor with Medtronic's AID algorithms, the system will allow for automatic insulin adjustments, ensuring glucose levels remain within the desired range. The CGM sensor, which is specifically tailored to work with Medtronic devices, will be created by Abbott and marketed by Medtronic.

These AID systems are designed to enhance health outcomes while alleviating the continuous decision-making burden faced by individuals with diabetes who rely on intensive insulin therapy. They will be particularly beneficial for the over 11 million people worldwide living with Type 1 and Type 2 diabetes who require multiple daily doses of rapid-acting insulin. Details regarding the financial aspects of the partnership and the timeline for commercial launch have not been disclosed.

Jared Watkin, executive vice president of Abbott's diabetes care business, said in a statement, "This partnership pairs two global leaders in glucose sensing technology and insulin delivery. Libre technology has set the standard for accurate, accessible, easy-to-use and reliable continuous glucose monitoring. Connecting this CGM built for Medtronic's insulin delivery systems and algorithms makes it easier for people to spend less time thinking about their diabetes and more time living."

Que Dallara, Executive Vice President and President at Medtronic Diabetes, "Our partnership with Abbott allows us to expand access to our advanced automated insulin delivery and smart MDI systems that deliver best-in-class outcomes with the most widely used CGM in the world. We're committed to simplifying diabetes management and making the transition to automated technology much more seamless for those who wish to achieve more with their diabetes care.”

This partnership with Medtronic marks the newest addition to Abbott's ongoing efforts to enhance diabetes care, providing individuals with greater options for managing their insulin confidently. Abbott's Libre single-analyte CGM technology is already accessible and integrated with automated insulin delivery solutions from various other insulin delivery manufacturers.